The American Journal of Gastroenterology· 2012Q1· Clinical trial
Clinical Guideline: Management of Gastroparesis
- 1,138citations
- Q1SCImago
- 2012year
Short summary
New clinical guidelines offer a structured approach to managing gastroparesis, emphasizing nutritional assessment, symptom relief, and glycemic control, while noting current treatments are inadequate.
AI-generated from the title and abstract; the full text is not read.
Key points
- Gastroparesis management requires assessment of nutritional state, symptom relief, and glycemic control.
- Current approved treatments like metoclopramide and GES offer limited efficacy.
- Nutritional support may involve oral modifications, jejunostomy tubes, or rarely parenteral nutrition.
- Many treatment options are based on open-label studies with small patient numbers.
AI-generated from the title and abstract; the full text is not read.
Abstract
This guideline presents recommendations for the evaluation and management of patients with gastroparesis. Gastroparesis is identified in clinical practice through the recognition of the clinical symptoms and documentation of delayed gastric emptying. Symptoms from gastroparesis include nausea, vomiting, early satiety, postprandial fullness, bloating, and upper abdominal pain. Management of gastroparesis should include assessment and correction of nutritional state, relief of symptoms, improvement of gastric emptying and, in diabetics, glycemic control. Patient nutritional state should be managed by oral dietary modifications. If oral intake is not adequate, then enteral nutrition via jejunostomy tube needs to be considered. Parenteral nutrition is rarely required when hydration and nutritional state cannot be maintained. Medical treatment entails use of prokinetic and antiemetic therapies. Current approved treatment options, including metoclopramide and gastric electrical stimulation (GES, approved on a humanitarian device exemption), do not adequately address clinical need. Antiemetics have not been specifically tested in gastroparesis, but they may relieve nausea and vomiting. Other medications aimed at symptom relief include unapproved medications or off-label indications, and include domperidone, erythromycin (primarily over a short term), and centrally acting antidepressants used as symptom modulators. GES may relieve symptoms, including weekly vomiting frequency, and the need for nutritional supplementation, based on open-label studies. Second-line approaches include venting gastrostomy or feeding jejunostomy; intrapyloric botulinum toxin injection was not effective in randomized controlled trials. Most of these treatments are based on open-label treatment trials and small numbers. Partial gastrectomy and pyloroplasty should be used rarely, only in carefully selected patients. Attention should be given to the development of new effective therapies for symptomatic control.
The authors' abstract, as published at the source. The American Journal of Gastroenterology, 2012 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Gastroenterology
GastroenterologyMedicine